Home/ Stocks/ ANNX

Annexon, Inc. Common Stock

ANNX XNAS

$5.29 +0.03 (+0.57%) ▲ 15-min delayed

Open

$5.21

High

$5.34

Low

$5.08

Volume

2.99M

Market Cap

$873.28M

About Annexon, Inc. Common Stock

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 93 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$0	$-55,348,000	$-0.28
Q1 2026	$0	$-44,142,000	$-0.23
FY 2025	$0	$-206,690,000	$-1.34
Q3 2025	$0	$-54,922,000	$-0.37

Earnings & Analyst Ratings

Next Earnings: Mon, Nov 9, 2026

Calendar →

Related Market News

No specific coverage for ANNX yet. Check out our latest market news or earnings calendar.

Get ANNX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Annexon, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.